anidulafungin

In some countries, anidulafungin is marketed under the brand name ECALTA.

unknown title 2011

ERAXIS anidulafungin for Injection belongs to the echinocandin class of antifungal drugs and is used to treat serious fungal infections caused by Candida, a yeast commonly found on the skin, in the digestive tract, or as a contaminant on medical equipment and devices.

unknown title 2011

Strong evidence for the cyst as the agent of transmission was provided by the failure of anidulafungin-treated mice to transmit the infection.

Elites TV 2010

We show for the first time that withdrawal of anidulafungin treatment with continued immunosuppression permitted the repopulation of cyst forms.

Elites TV 2010

Pfizer said today that Eraxis (anidulafungin) has been approved by the U.S. Food and

THE MEDICAL NEWS 2010

Pfizer said today that Eraxis (anidulafungin) has been approved by the U.S.

THE MEDICAL NEWS 2009

About Ecalta (anidulafungin) - Results from a double-blind pivotal clinical trial of 245 patients with invasive candidasis

Health News from Medical News Today 2009

In addition to the cost benefits and equivalent efficacy, anidulafungin has advantages over existing treatments - with no dose adjustments required in patients with renal or hepatic impairment.

Medlogs - Recent stories 2008

Dr David Gillen, Medical Director, Pfizer Limited, said: "We are delighted that the SMC has recognised the valuable role that anidulafungin can play in the management of these life threatening infections and is an important medicine for critically ill patients."

Medlogs - Recent stories 2008

Pfizer Limited today welcomes the Scottish Medicines Consortium (SMC) advice, which recommends Ecalta® (anidulafungin), a new antifungal medicine for the treatment of invasive candidiasis in NHS Scotland. 1

Medlogs - Recent stories 2008